HER2-positive breast cancer represents 15%-20% of breast malignancies and is characterized by an aggressive behavior and high recurrence rates. Anti-HER2-directed agents represent the mainstay of treatment of p
It is important to have a say in your treatment for HR+/HER2- early breast cancer. Learn the best way to do that. Article Factors That May Impact Your Care Plan You’ll get a better understanding of treatment options when you know the things that guide your doctor’s recommendations. Lea...
Is HER2 breast cancer curable? What is DCIS breast cancer? How does bronchogenic carcinoma cancer metastasis? What is neoadjuvant chemotherapy breast cancer? How is stage 1 testicular cancer treated? What is nuclear grade in breast cancer?
Approximately 15%–30% of breast cancers have overexpression or amplification of human epidermal growth factor receptor 2 (HER2), which is associated
Patients with a type of breast cancer called HER2-positive are less likely to survive if their initial treatment fails to eradicate the tumor completely and they have high levels of immune cells called tumor infiltrating lymphocytes in the residual disea
Breast cancer that expresses HER2 is known as HER2-positive and HER2-low depending on how many HER2 proteins are on the cells. These types of breast cancer may be able to be treated by Enhertu (fam-trastuzumab deruxtecan-nxki). In most cases, you will have to have tried another HER2-...
Women who are in remission for breast cancer should adopt a diet based on their breast cancer types. The goal is to reduce recurrence risk. However, note that breast cancer can recur with a different ER, PR and/or HER2 status than the initial primary tumor. In fact, discordance between ...
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382:1021–8. https://doi.org/10.1016/S0140-6736(13)61094-6. Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial ...
HER2- breast cancer. Moreover, these results substantiate the statistically significant near doubling of median overall survival observed in the earlier randomized IND-213 study in a similar patient population treated with pelareorep + chemo...
Chemotherapy could be recommended for many women diagnosed using early-stage breast cancer when cancer remains hormone-receptor-negative and HER2-positive. Both these attributes are connected with cancer which is more competitive. A genomic evaluation can assist some women diagnosed using autoimmune diseas...